Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.

Sean Wharton, Rachel L Batterham, Meena Bhatta, Silvio Buscemi, Louise N Christensen, Juan P Frias, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A Wadden, W Timothy Garvey

Journal: Obesity (Silver Spring, Md.) 2023;31(3):703-715

PMID: 36655300

Full Text on Wiley View on PubMed

Abstract

OBJECTIVE

This study evaluated the effect of once-weekly semaglutide 2.4 mg on 2-year control of eating.

METHODS

In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks. A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants. P values were not controlled for multiplicity.

RESULTS

In participants completing the Control of Eating Questionnaire (semaglutide, n = 88; placebo, n = 86), mean body weight changes were -14.8% (semaglutide) and -2.4% (placebo). Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 (p < 0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 (p < 0.05); and for hunger and fullness at week 20 (p < 0.001). Improvements in craving domain scores were positively correlated with reductions in body weight from baseline to week 104 with semaglutide. At 104 weeks, scores for desire to eat salty and spicy food, cravings for dairy and starchy foods, difficulty in resisting cravings, and control of eating were significantly reduced with semaglutide versus placebo (all p < 0.05).

CONCLUSIONS

In adults with overweight/obesity, semaglutide 2.4 mg improved short- and longer-term control of eating associated with substantial weight loss.

Address: York University, McMaster University, and Wharton Weight Management Clinic, Burlington, Ontario, Canada.; Division of Medicine, University College London Centre for Obesity Research, University College London, London, UK.; National Institute of Health Research, University College London Hospital Biomedical Research Centre, London, UK.; Centre for Weight Management and Metabolic Surgery, University College London Hospital, London, UK.; Novo Nordisk A/S, Søborg, Denmark.; Unit of Clinical Nutrition, Policlinico University Hospital, Palermo, Italy.; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.; National Research Institute, Los Angeles, California, USA.; School of Medicine, Universidad Europea de Madrid, Madrid, Spain.; Department of Endocrinology and Nutrition Service, Hospital Universitario Quironsalud Madrid, Madrid, Spain.; Department of Bariatric Surgery, St George Private Hospital, Sydney, New South Wales, Australia.; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.

DOI: 10.1002/oby.23673

Link outs

Free resources

Medical:

https://clinicaltrials.gov/search?term=AREA%5BRefe...

Subscription / membership required

Full Text Sources:

https://doi.org/10.1002/oby.23673

MeSH Terms: Adult, Humans, Overweight, Eating, Obesity, Body Weight, Craving